Clinical Pharmacology

Full Course:  20 AMA PRA Category 1 Credits for CME / CEU / CPD

Short Course:  10 AMA PRA Category 1 Credits for CME / CEU / CPD

Course(s) are appropriate for:  Family Practitioners, Pediatricians, Internists, General Practitioners, Nurses, Nurse Practitioners, and Physician Assistants (PA-C's)

Series 13 (CP13) Topics Include:  

To view topic outline of the full or short course, select the Course Type (Full or Short) below:

AVAILABLE ONLY AS DOWNLOAD; DISC FORMAT NOT AVAILABLE

Full Course:
CP13
Full Course Price:
$580
Short Course:
CP13A, CP13B
Short Course Price:
$485
Format:
Available in Audio format.

Course Topics

Antipsychotic Agents in Pediatric Patients

Titrate dosing of antipsychotic medications in children; Optimize treatment of a child with bipolar depression or mania; Summarize the findings of the TEAM study; Address hyperprolactinemia in a child on an atypical antipsychotic; Cite short- and long-term side effects of antipsychotic medications with the family of a child with a psychiatric disorder.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Beyond Glucocorticoids: The Expanding List of Medications Associated with Osteoporosis

Choose appropriate measures to treat osteoporosis caused by drugs that reduce levels of sex hormones; Compensate for the limitations of the Fracture Risk Assessment Tool (FRAX) when assessing fracture risk in patients with diabetes; Prescribe appropriate doses of the oral GnRH antagonist elagolix for pain from endometriosis, considering its dose-dependent association with osteoporosis; Summarize the relative risk for osteoporosis presented by various classes of antidiabetic medications; Evaluate independent and drug-related causes of fracture in patients with epilepsy.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Updates on Lymphomas and Chronic Lymphocytic Leukemia

Cite the outcome of the RELEVANCE trial, which explored treating follicular lymphoma with a lenalidomide-rituximab ('R-squared") regimen; Explain the mechanism of action of rapid lymphocytosis in patients treated for chronic lymphocytic leukemia; Identify unique side effects of targeted agents used for treating lymphomas; Manage a patient with mantle cell lymphoma; Summarize the findings of the MURANO trial of venetoclax-rituximab for treating relapsed or refractory chronic lymphocytic leukemia.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Update on Bipolar Disorder

Treat a patient on lithium; Summarize the findings of the BALANCE trial; Recognize the manic and depressive symptoms associated with juvenile BPD; Screen for common psychiatric comorbidities associated with juvenile BPD; Consider an appropriate treatment strategy for a youth with BPD.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Safe Deprescribing of Benzodiazepines

Identify appropriate and inappropriate uses of benzodiazepines; Select effective modalities to treat anxiety related to cognitive dysfunction; Recognize the symptoms of withdrawal from benzodiazepines; Consider pharmacokinetic and pharmacodynamics factors when planning withdrawal from benzodiazepines; Develop plans to taper chronic use of benzodiazepines.

QUALIFIES FOR GERIATRICS, CLINICAL PHARMACOLOGY AND CONTROLLED SUBSTANCES

Management of Sexual Side Effects of Psychotropic Medication

Summarize the roles of the hormones that affect the sexual response; Characterize the relationship between depression and sexual dysfunction; Recommend an appropriate neuroleptic drug for a patient with a psychotic disorder who needs medication but is concerned about a history of sexual dysfunction on psychotropic agents; Choose a mood stabilizer for a patient with bipolar disorder who has a history of sexual dysfunction on medications; Manage a patient with sexual dysfunction who is taking a selective serotonin reuptake inhibitor.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Update on Lymphoma

Provide effective options for managing toxicities in patients receiving chimeric antigen receptor (CAR) T cell therapy for lymphoma; Elaborate on the association between the rate of proliferation of chimeric antigen receptor (CAR) T cells and toxicity in patients receiving CAR T cell therapy; Identify factors associated with clinical remission of lymphoma after chimeric antigen receptor (CAR) T cell therapy; Optimize treatment of patients with diffuse large B cell lymphoma or mantle cell lymphoma based on clinical characteristics and burden of disease; Recognize toxicities commonly associated with treatments for diffuse large B cell lymphoma and relapsed or refractory mantle cell lymphoma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Psychosis in Neurodegenerative Disorders

Identify the types of dementia that are most commonly associated with psychosis. Distinguish among the typical manifestations of psychosis in patients with dementia and those with primary psychiatric disorders; Recognize signs and symptoms of Lewy body disease; Counsel the family of a patient who presents with psychosis in dementia; Select appropriate medications for patients with psychosis in dementia.

QUALIFIES FOR CLINICAL PHARMACOLOGY/QUALIFIES FOR GERIATRICS

Breast Cancer Update

Use gene assays to predict responsiveness to endocrine therapy and chemotherapy; Discuss the potential utility of circulating tumor DNA to select targeted therapy for patients with breast cancer; List possible clinical and mechanistic uses for neoadjuvant endocrine therapy; Summarize the relationship between Ki67 inhibition after neoadjuvant therapy and clinical outcomes; Identify possible benefits of adding targeted therapy to endocrine therapy in the neoadjuvant setting.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Immunotherapy for Gynecologic Malignancies/Genomics-based Personalized Care for Colorectal Cancer

Select therapeutic combinations that include immune checkpoint inhibitors for ovarian, cervical, and endometrial cancer; Identify emerging approaches involving autologous immune cell therapies and vaccine-based therapies in gynecologic cancers; Characterize the immune microenvironment of tumors in ovarian cancer; Identify common targetable gene alterations in colorectal cancer; Use appropriate combinations of targeted therapy for colorectal cancer harboring a targetable mutation.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Accreditation

Additional Information

Additional Continuing Medical Education options available:

Other courses of interest may include: Alternative Medicine, Family Practice and Psychiatry